Cargando…
Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers
(i) Background: ChAdOx1 nCoV-19 (Covishield(®)) vaccine is widely used in India. We studied the Covishield(®) induced antibody response and its durability among health care workers (HCWs) (ii) Method: HCWs received two doses (0.5 mL) four weeks apart. Blood specimens, collected before each dose, day...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863895/ https://www.ncbi.nlm.nih.gov/pubmed/36679930 http://dx.doi.org/10.3390/vaccines11010084 |
_version_ | 1784875448402968576 |
---|---|
author | Verma, Alka Goel, Amit Katiyar, Harshita Tiwari, Prachi , Mayank Sana, Asari Khetan, Dheeraj Bhadauria, Dharmendra Singh Raja, Ajay Khokher, Neelam , Shalimar Singh, Ratendra Kumar Aggarwal, Amita |
author_facet | Verma, Alka Goel, Amit Katiyar, Harshita Tiwari, Prachi , Mayank Sana, Asari Khetan, Dheeraj Bhadauria, Dharmendra Singh Raja, Ajay Khokher, Neelam , Shalimar Singh, Ratendra Kumar Aggarwal, Amita |
author_sort | Verma, Alka |
collection | PubMed |
description | (i) Background: ChAdOx1 nCoV-19 (Covishield(®)) vaccine is widely used in India. We studied the Covishield(®) induced antibody response and its durability among health care workers (HCWs) (ii) Method: HCWs received two doses (0.5 mL) four weeks apart. Blood specimens, collected before each dose, day (D) 60, D150 and D270 after second dose, were tested for anti-spike antibody (ASAb) titre and neutralising antibody (%) (NAb) using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 NAb ELISA Kit (Invitrogen), respectively. Data are expressed as proportions and median (interquartile range) and compared using non-parametric (iii) Result: Among 135 HCWs (83 males; age 45 (37–53); 36 had pre-existing ASAb), 29 (21.5%) acquired COVID-19 after 60 (39–68) days of vaccination. ASAb titre before second dose and at D60, D150, D270 were 77.2 (19.4–329.4), 512 (114.5–9212), 149 (51.6–2283) and 2079 (433.9–8644) U/mL, respectively. Compared to those without pre-existing ASAb, titres were significantly higher before second dose (5929 vs. 41, p < 0.001), D60 (3395 vs. 234, p = 0.007) and D150 (1805 vs. 103, p < 0.001) in participants with pre-existing ASAb; NAb were also higher (80 vs. 18, p < 0.001) before second dose. Between those who acquired infection or not after vaccination, ASAb titres were comparable before second dose (77 vs. 78, p = 0.362) but significantly higher at D60 (14,019 vs. 317, p < 0.001) and D150 (2062 vs. 121, p = 0.002) in the former group, though NAb percentage were higher at D60 (87 vs. 27, p < 0.001) and D150 (79 vs. 25, p = 0.007) only (iv) Conclusions: Covishield(®) induces a higher antibody titre in those with pre-existing ASAb. The vaccine induced antibody starts falling 5 months after vaccination. |
format | Online Article Text |
id | pubmed-9863895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98638952023-01-22 Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers Verma, Alka Goel, Amit Katiyar, Harshita Tiwari, Prachi , Mayank Sana, Asari Khetan, Dheeraj Bhadauria, Dharmendra Singh Raja, Ajay Khokher, Neelam , Shalimar Singh, Ratendra Kumar Aggarwal, Amita Vaccines (Basel) Article (i) Background: ChAdOx1 nCoV-19 (Covishield(®)) vaccine is widely used in India. We studied the Covishield(®) induced antibody response and its durability among health care workers (HCWs) (ii) Method: HCWs received two doses (0.5 mL) four weeks apart. Blood specimens, collected before each dose, day (D) 60, D150 and D270 after second dose, were tested for anti-spike antibody (ASAb) titre and neutralising antibody (%) (NAb) using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 NAb ELISA Kit (Invitrogen), respectively. Data are expressed as proportions and median (interquartile range) and compared using non-parametric (iii) Result: Among 135 HCWs (83 males; age 45 (37–53); 36 had pre-existing ASAb), 29 (21.5%) acquired COVID-19 after 60 (39–68) days of vaccination. ASAb titre before second dose and at D60, D150, D270 were 77.2 (19.4–329.4), 512 (114.5–9212), 149 (51.6–2283) and 2079 (433.9–8644) U/mL, respectively. Compared to those without pre-existing ASAb, titres were significantly higher before second dose (5929 vs. 41, p < 0.001), D60 (3395 vs. 234, p = 0.007) and D150 (1805 vs. 103, p < 0.001) in participants with pre-existing ASAb; NAb were also higher (80 vs. 18, p < 0.001) before second dose. Between those who acquired infection or not after vaccination, ASAb titres were comparable before second dose (77 vs. 78, p = 0.362) but significantly higher at D60 (14,019 vs. 317, p < 0.001) and D150 (2062 vs. 121, p = 0.002) in the former group, though NAb percentage were higher at D60 (87 vs. 27, p < 0.001) and D150 (79 vs. 25, p = 0.007) only (iv) Conclusions: Covishield(®) induces a higher antibody titre in those with pre-existing ASAb. The vaccine induced antibody starts falling 5 months after vaccination. MDPI 2022-12-30 /pmc/articles/PMC9863895/ /pubmed/36679930 http://dx.doi.org/10.3390/vaccines11010084 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Verma, Alka Goel, Amit Katiyar, Harshita Tiwari, Prachi , Mayank Sana, Asari Khetan, Dheeraj Bhadauria, Dharmendra Singh Raja, Ajay Khokher, Neelam , Shalimar Singh, Ratendra Kumar Aggarwal, Amita Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers |
title | Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers |
title_full | Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers |
title_fullStr | Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers |
title_full_unstemmed | Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers |
title_short | Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers |
title_sort | durability of chadox1 ncov-19 (covishield(®)) vaccine induced antibody response in health care workers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863895/ https://www.ncbi.nlm.nih.gov/pubmed/36679930 http://dx.doi.org/10.3390/vaccines11010084 |
work_keys_str_mv | AT vermaalka durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT goelamit durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT katiyarharshita durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT tiwariprachi durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT mayank durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT sanaasari durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT khetandheeraj durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT bhadauriadharmendrasingh durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT rajaajay durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT khokherneelam durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT shalimar durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT singhratendrakumar durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers AT aggarwalamita durabilityofchadox1ncov19covishieldvaccineinducedantibodyresponseinhealthcareworkers |